No written informed consent by individual or caregiver and/orno written assent by minors.Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, severe anemia (below 80g/l Hb according to WHO22) upon initial clinical assessment.History of acute or severe chronic disease.Recent use of anthelmintic drug (within past 4 weeks).Attending other clinical trials during the study.Pregnancy, lactating and/or planning to become pregnantwithin the study period.Known allergy to study medications (i.e., albendazole, ivermectin or moxidectin). Here, GSTM1 is linked to allergic disease.